Lead Generation Strategies
Modern Small Molecule Discovery, Design, and Optimization for Next-Generation Therapeutics
29 September - October 1, 2026 ALL TIMES EDT
Today’s small molecule drug discovery or design stems from a myriad of sources other than, or in addition to, the traditional high-throughput screening of physically present large chemical compound libraries. Not only are there are more types of libraries available—from physical to virtual chemical collections, covering a wider range of chemical space—but there are more tools to interrogate target and drug compound engagement upon which to make initial or subsequent rational drug design decisions or drug lead selection choices. Join us at Cambridge Healthtech Institute’s Lead Generation Strategies to learn, via case studies from leading industry ‘drug hunters,’ when, where, and how to use various small molecule drug-finding or design approaches and even more importantly, how to capitalize on integrating the various options.
Preliminary Agenda

BIOPHYSICAL APPROACHES FOR SMALL MOLECULE DRUG DISCOVERY

Enhancing Small Molecule Lead Discovery with Ultra-High-Throughput Mass Spectrometry

Photo of Fan Pu, PhD, Senior Scientist II, AbbVie Inc. , Senior Scientist II , AbbVie Inc
Fan Pu, PhD, Senior Scientist II, AbbVie Inc. , Senior Scientist II , AbbVie Inc

Native Mass Spectrometry Screening Applied to TNFα Small Molecule Lead Generation 

Raphael Reinbold, PhD, Senior Scientist II, Platform, OMass Therapeutics , Sr Scientist II , Platform , OMass Therapeutics

Making Your Hits Your Early Leads: Innovative SPR Applications

Photo of John Quinn, PhD, Distinguished Scientist, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech , Distinguished Scientist & Head , Biochemistry & Cellular Pharmacology , Genentech Inc
John Quinn, PhD, Distinguished Scientist, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech , Distinguished Scientist & Head , Biochemistry & Cellular Pharmacology , Genentech Inc

Covalent and Non-covalent Lead Generation Strategies for VRK1, a Paralog Synthetic Lethal Target in Cancer

Photo of Kasia Handing, PhD, Associate Director, Structural Biology, Tango Therapeutics , Associate Director , Biochemistry , Tango Therapeutics
Kasia Handing, PhD, Associate Director, Structural Biology, Tango Therapeutics , Associate Director , Biochemistry , Tango Therapeutics

Ninhydrin as a Covalent Warhead Targeting Arginine

Photo of Balyn Zaro, PhD, Associate Professor, Pharmaceutical Chemistry, University of California San Francisco , Associate Professor , Pharmaceutical Chemistry , Univ of California San Francisco
Balyn Zaro, PhD, Associate Professor, Pharmaceutical Chemistry, University of California San Francisco , Associate Professor , Pharmaceutical Chemistry , Univ of California San Francisco

Covalent molecules have emerged as next-generation therapeutics and as powerful tools for perturbing fundamental biological processes. Chemical proteomic methods to screen for reactive proteinaceous amino acids have transformed small-molecule discovery pipelines, but their application remains mostly limited to sites where reactive cysteines and lysines are present. Here we report a ninhydrin-based warhead that selectively modifies arginine residues, thus expanding the repertoire of amino acids targetable by covalent molecules. These studies uncovered potential modification sites on disease-relevant proteins, including reactive arginines within catalytic sites that are essential for function. By endowing a reversible small molecule inhibitor of cyclophilin A with a ninhydrin warhead, we achieved selective, covalent engagement, and attenuation of enzymatic activity, highlighting the potential for targeting arginines in future therapeutic development campaigns.

Covalent and Reversible Inhibitor Discovery: Integrating DEL & Fragment-Based Drug Discovery Approaches

Photo of Xiaojie Bruce Lu, PhD, Professor & Principal Investigator, Chemical Biology Research Center, Chinese Academy of Sciences , Prof & Principal Investigator , Chemical Biology Research Ctr , SIMM, CAS
Xiaojie Bruce Lu, PhD, Professor & Principal Investigator, Chemical Biology Research Center, Chinese Academy of Sciences , Prof & Principal Investigator , Chemical Biology Research Ctr , SIMM, CAS

DNA encoded focused library has became an efficient strategy for hit identification and hit to lead optimization for specific target protein. However, the design and synthesis of target focused library is still a challenge for many protein targets. Integrating DEL with chemoproteomics could be an effective and practicable strategy for the target focused library technology development. This talk will highlight recent advancement of the technology integration between DEL and other drug discovery technologies such as FBDD and chemoproteomics for the reversible and covalent Inhibitors discovery. 

Using Metal Ions to Identify Novel PPI Binding Sites

Photo of Gozde Ulas, PhD, Principal Scientist, Biochemical and Cellular Pharmacology, Genentech Inc. , Principal Scientist , Biochemical and Cellular Pharmacology , Genentech Inc
Gozde Ulas, PhD, Principal Scientist, Biochemical and Cellular Pharmacology, Genentech Inc. , Principal Scientist , Biochemical and Cellular Pharmacology , Genentech Inc

TARGETING G PROTEIN–COUPLED RECEPTORS (GPCRS)

Fragment Screening and Hit Optimization for an Orphan GPCR Using 19F-NMR and SPR Techniques

Photo of Kris A. Borzilleri, Principal Scientist, Structural Biology & Molecular Sciences, Pfizer Global R&D, Groton Labs , Principal Scientist , Structural Biology & Molecular Sciences , Pfizer Global R&D Groton Labs
Kris A. Borzilleri, Principal Scientist, Structural Biology & Molecular Sciences, Pfizer Global R&D, Groton Labs , Principal Scientist , Structural Biology & Molecular Sciences , Pfizer Global R&D Groton Labs

Membrane Mimetics in Drug Discovery for GPCRs and Beyond

Photo of Matthew T. Eddy, PhD, Assistant Professor, Chemistry, University of Florida, Gainesville , Assistant Professor , Chemistry , University of Florida Gainesville
Matthew T. Eddy, PhD, Assistant Professor, Chemistry, University of Florida, Gainesville , Assistant Professor , Chemistry , University of Florida Gainesville

Latest Methods for GPCR-Biased Ligand Discovery

Photo of Dmitry Veprintsev, Professor of Molecular & Cellular Pharmacology, University of Nottingham; Co-Founder and CEO, Z7 Biotech Ltd. , Professor , Molecular & Cellular Pharmacology , University of Nottingham
Dmitry Veprintsev, Professor of Molecular & Cellular Pharmacology, University of Nottingham; Co-Founder and CEO, Z7 Biotech Ltd. , Professor , Molecular & Cellular Pharmacology , University of Nottingham

Exploring GPCR Allostery Using High-Throughput DEL Screening

Photo of Evan O'Brien, PhD, Assistant Professor, Biophysics & Biophysical Chemistry, The Johns Hopkins University School of Medicine , Assistant Professor , Biophysics & Biophysical Chemistry , Johns Hopkins University
Evan O'Brien, PhD, Assistant Professor, Biophysics & Biophysical Chemistry, The Johns Hopkins University School of Medicine , Assistant Professor , Biophysics & Biophysical Chemistry , Johns Hopkins University

DNA-ENCODED LIBRARY APPLICATIONS

DEL Applications to Protein Degrader Discovery

Photo of Carol Mulrooney, PhD, Investigator, Cheminformatics, GlaxoSmithKline , Principal Investigator , Cheminformatics , GSK
Carol Mulrooney, PhD, Investigator, Cheminformatics, GlaxoSmithKline , Principal Investigator , Cheminformatics , GSK

Advancing Lead Generation: Overcoming Selectivity Challenges with DNA-Encoded Libraries

Photo of Srinivas Chamakuri, PhD, Assistant Professor, Pathology & Immunology, Baylor College of Medicine , Asst Prof , Pathology & Immunology , Baylor College of Medicine
Srinivas Chamakuri, PhD, Assistant Professor, Pathology & Immunology, Baylor College of Medicine , Asst Prof , Pathology & Immunology , Baylor College of Medicine

Extracting Actionable SAR from Primary DEL Screens to Drive Early Lead Optimization

Photo of Justin Montgomery, PhD, Director, Machine Learning and Computational Sciences, Pfizer , Director , Machine Learning and Computational Sciences , Pfizer Inc
Justin Montgomery, PhD, Director, Machine Learning and Computational Sciences, Pfizer , Director , Machine Learning and Computational Sciences , Pfizer Inc

Primary DNA-encoded library (DEL) screens identify binders from millions of related compounds, but translating sequencing readouts into actionable SAR requires a systematic approach. This talk describes a practical method for extracting positive and negative SAR directly from primary DEL data and applying it to early hit optimization. Case studies illustrate the approach, which is implemented in a web-based platform integrating DEL SAR and analyses for early, data-driven decision-making.

DNA-Encoded Library (DEL) Technology for Covalent Drug Discovery

Photo of Jeff A. Messer, Director, Analytics, Encoded Libraries Technology, GlaxoSmithKline , Director, Analytics , Encoded Libraries Technology , GSK
Jeff A. Messer, Director, Analytics, Encoded Libraries Technology, GlaxoSmithKline , Director, Analytics , Encoded Libraries Technology , GSK

Plenary Keynote Tuesday

OPENING PLENARY KEYNOTE PANEL (SEPTEMBER 29)

Panel Moderator:

Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach

Dennis Hu, PhD, CEO, Drug Hunter Inc. , CEO , Drug Hunter Inc.

Panelists:

Erin Davis, PhD, Vice President, Research Business Insights & Technology, Bristol Myers Squibb , VP , Research Business Insights & Technology , Bristol Myers Squibb

Ryan Potts, PhD, Executive Director and Head, Induced Proximity Platform, Amgen, Inc. , Executive Director and Head , Induced Proximity Platform , Amgen

John Tallarico, PhD, Global Head, Discovery Sciences, Novartis BioMedical Research , Global Head , Discovery Sciences , Novartis BioMedical Research

Andrea Weston, PhD, Head of Discovery Biology and Pharmacology, Pfizer Inc. , Exec Dir Cellular Genomics & Protein , Cellular & Genomics & Protein Sciences , Pfizer Inc.

David Wilson, PhD, Vice President & Global Head, Oncology Chemistry & DMPK, AstraZeneca , VP & Global Head , Oncology Chemistry & DMPK , AstraZeneca

Plenary Keynote Thursday

CLOSING PLENARY KEYNOTE PANEL (OCTOBER 1)

Panel Moderator:

Starting Up: Translating Lab Ideas into Commercial Impact

Armon Sharei, PhD, Founder & CEO, Portal Biotechnologies , Founder & CEO , Portal Biotechnologies

Panelists:

Sangeeta N. Bhatia, Professor, Director Marble Center for Cancer Nanomedicine, Health Sciences & Technology, Massachusetts Institute of Technology , Professor, Director Marble Center for Cancer Nanomedicine , Health Sciences & Technology , Massachusetts Institute of Technology

Kris Elverum, MBA, Former President & CEO, AIRNA , Former President & CEO , AIRNA

Parastoo Khoshakhlagh, PhD, Co-Founder & CEO, GC Therapeutics , Co-Founder & CEO , GC Therapeutics

PLENARY KEYNOTE VC PANEL

PLENARY PANEL: INSIGHTS FROM VENTURE CAPITALISTS (SEPTEMBER 30)

Panel Moderator:

Venture-Capitalist Insights on Trends in Drug Discovery

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

Panelists:

Chris De Savi, PhD, CSO Partner, Curie Bio , CSO Partner , Curie.Bio

Neil Kubica, PhD, Therapeutics Division Lead, General Inception , Therapeutics Division Lead , General Inception

Pengpeng Li, PhD, Principal, Lilly Asia Ventures , Principal , Lilly Asia Ventures


For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431

Email: kskahan@healthtech.com